Although China has a vibrant domestic CLIA sector, the country’s MDx market is expanding rapidly and opportunities abound.!--h2>
Enal Razvi, Ph.D.
This GEN Report Provides a Snapshot of the China In vitro Diagnostics Marketplace based on Primary Market Analysis
Infectious Disease Testing Contributes to the Bulk of this Space Currently—with Few Disease Classes Dominating Revenue Generation Today
The Field is Fragmented with Thousands of End-User Laboratories where Testing is Performed
Both Local as well as Multinational Companies are Active in this Marketplace
Oncology Testing Represents a Future Growth Opportunity for this Marketplace and Offers Entry Opportunity to Technology Providers to Establish Partnerships with Local Companies to Participate in this Growth
Enal Razvi, Ph.D., conducted his doctoral work on viral immunology and subsequent to receiving his Ph.D. went on to the Rockefeller University in New York to serve as Aaron Diamond Post-doctoral fellow under Professor Ralph Steinman [Nobel Prize Winner in 2011 for his discovery of dendritic cells in the early-70s with Zanvil Cohn]. Subsequently, Dr. Razvi completed his research fellowship at Harvard Medical School. For the last two decades Dr. Razvi has worked with small and large companies and consulted for more than 100 clients worldwide. He currently serves as Biotechnology Analyst and Managing Director of SelectBio U.S. He can be reached at email@example.com.